Researchers at Mayo Clinic in Florida, US, have been able to shut down one of the most lethal forms of lung cancer by administering a combination of rheumatoid arthritis drug auranofin and an experimental targeted agent.
The combination therapy worked in a lab study to stop lung adenocarcinoma associated with mutation of the KRAS gene.
Senior author Alan Fields said the combination therapy might work in other KRAS-mediated cancers, such as colon and pancreatic cancers, as well as other cancer types.
It was found that the combination therapy shuts down a major signaling pathway, or set of molecular mechanisms, that stimulates the growth of cancer stem cells in KRAS-mediated lung adenocarcinoma.
The study has been published in the journal Cancer Cell.